Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 2, 2015, Pages 488-493

  Fromen, Catherine A ^a   Robbins, Gregory R ^b   Shen, Tammy W ^b   Kai, Marc P ^a   Ting, Jenny P Y ^b   De Simone, Joseph M ^a,b  

^a North Carolina State University   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cationic; Mucosal; Nanoparticle; Pulmonary; Vaccine

Indexed keywords

ANTIGEN; B7 ANTIGEN; CD19 ANTIGEN; CD86 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; OVALBUMIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; CHEMOKINE; CYTOKINE; HYDROGEL; LIGAND; SUBUNIT VACCINE; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; GERMINAL CENTER; HUMORAL IMMUNITY; HYDROGEL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; INTERNALIZATION; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY IMMUNIZATION; SURFACE CHARGE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; IMMUNOLOGY; LUNG; METABOLISM; PROCEDURES; STATIC ELECTRICITY; SURFACE PROPERTY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODY FORMATION; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; HYDROGELS; IMMUNITY, MUCOSAL; IMMUNIZATION; LIGANDS; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NANOPARTICLES; OVALBUMIN; STATIC ELECTRICITY; SURFACE PROPERTIES; TOLL-LIKE RECEPTORS; VACCINES, SUBUNIT;

EID: 84920982307     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1422923112     Document Type: Article

References (33)

1. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: The promise and the challenge. Nat Rev Immunol 6(2):148-158.
2. Blank F, Stumbles P, von Garnier C (2011) Opportunities and challenges of the pulmonary route for vaccination. Expert Opin Drug Deliv 8(5):547-563.
3. Borges O, Lebre F, Bento D, Borchard G, Junginger HE (2010) Mucosal vaccines: Recent progress in understanding the natural barriers. Pharm Res 27(2):211-223.
4. Qi H, et al. (2014) Follicular T-helper cells: Controlled localization and cellular interactions. Immunol Cell Biol 92(1):28-33.
5. Jacobson EB, Caporale LH, Thorbecke GJ (1974) Effect of thymus cell injections on germinal center formation in lymphoid tissues of nude (thymusless) mice. Cell Immunol 13(3):416-430.
6. Inaba K, Steinman RM, Van Voorhis WC, Muramatsu S (1983) Dendritic cells are critical accessory cells for thymus-dependent antibody responses in mouse and in man. Proc Natl Acad Sci USA 80(19):6041-6045.
7. Rickert RC, Rajewsky K, Roes J (1995) Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 376(6538):352-355.
8. Smith DM, Simon JK, Baker JR, Jr (2013) Applications of nanotechnology for immunology. Nat Rev Immunol 13(8):592-605.
9. Zhao L, et al. (2014) Nanoparticle vaccines. Vaccine 32(3):327-337.
10. Hardy CL, et al. (2013) Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints. J Immunol 191(10):5278-5290.
11. Kunda NK, Somavarapu S, Gordon SB, Hutcheon GA, Saleem IY (2013) Nanocarriers targeting dendritic cells for pulmonary vaccine delivery. Pharm Res 30(2):325-341.
12. Pulliam B, Sung JC, Edwards DA (2007) Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin Drug Deliv 4(6):651-663.
13. Wang YY, et al. (2008) Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl 47(50):9726-9729.
14. Debin A, et al. (2002) Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 20(21-22):2752-2763.
15. Gupta NK, Tomar P, Sharma V, Dixit VK (2011) Development and characterization of chitosan coated poly-(e-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine 29(48):9026-9037.
16. Nembrini C, et al. (2011) Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci USA 108(44):E989-E997.
17. Li AV, et al. (2013) Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med 5(204):ra130.
18. Roberts RA, et al. (2013) Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano-and microscale particles. PLoS ONE 8(4):e62115.
19. Watanabe J, Miyazaki Y, Zimmerman GA, Albertine KH, McIntyre TM (2003) Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity. J Biol Chem 278(43):42361-42368.
20. Good-Jacobson KL, Tarlinton DM (2012) Multiple routes to B-cell memory. Int Immunol 24(7):403-408.
21. Parker DC (1993) T cell-dependent B cell activation. Annu Rev Immunol 11:331-360.
22. Christensen D, et al. (2009) Liposome-based cationic adjuvant formulations (CAF): Past, present, and future. J Liposome Res 19(1):2-11.
23. Korsholm KS, et al. (2007) The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121(2):216-226.
24. Ma Y, et al. (2011) The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale 3(5): 2307-2314.
25. Slütter B, Jiskoot W (2010) Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination. J Control Release 148(1):117-121.
26. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE (2001) Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14(3):201-207.
27. Koppolu B, Zaharoff DA (2013) The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cells. Biomaterials 34(9):2359-2369.
28. Choi HS, et al. (2010) Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol 28(12):1300-1303.
29. Furuhashi K, et al. (2012) Mouse lung CD103+ and CD11bhigh dendritic cells preferentially induce distinct CD4+ T-cell responses. Am J Respir Cell Mol Biol 46(2): 165-172.
30. Coch C, et al. (2009) Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA. J Leukoc Biol 86(3):663-670.
31. Gilliet M, Cao W, Liu YJ (2008) Plasmacytoid dendritic cells: Sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 8(8):594-606.
32. Garcia A, et al. (2012) Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications. J Drug Deliv 2012:941243.
33. Perry JL, et al. (2012) PEGylated PRINT nanoparticles: The impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics. Nano Lett 12(10):5304-5310.